Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study.
Eerkens AL, Brummel K, Vledder A, Paijens ST, Requesens M, Loiero D, van Rooij N, Plat A, Haan FJ, Klok P, Yigit R, Roelofsen T, de Lange NM, Klomp R, Church D, Ter Elst A, Wardenaar R, Spierings D, Foijer F, Koelzer VH, Bosse T, Bart J, Jalving M, Reyners AKL, de Bruyn M, Nijman HW. Eerkens AL, et al. Among authors: nijman hw. Nat Commun. 2024 Sep 3;15(1):7695. doi: 10.1038/s41467-024-52098-8. Nat Commun. 2024. PMID: 39227583 Free PMC article. Clinical Trial.
Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study.
Vermeij R, Leffers N, Hoogeboom BN, Hamming IL, Wolf R, Reyners AK, Molmans BH, Hollema H, Bart J, Drijfhout JW, Oostendorp J, van der Zee AG, Melief CJ, van der Burg SH, Daemen T, Nijman HW. Vermeij R, et al. Among authors: nijman hw. Int J Cancer. 2012 Sep 1;131(5):E670-80. doi: 10.1002/ijc.27388. Epub 2012 Jan 31. Int J Cancer. 2012. PMID: 22139992 Clinical Trial.
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.
Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, Leary A, Edmondson RJ, Powell ME, Crosbie EJ, Kitchener HC, Mileshkin L, Pollock PM, Smit VT, Creutzberg CL. Stelloo E, et al. Among authors: nijman hw. Mod Pathol. 2015 Jun;28(6):836-44. doi: 10.1038/modpathol.2015.43. Epub 2015 Feb 27. Mod Pathol. 2015. PMID: 25720322 Free article.
POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.
van Gool IC, Eggink FA, Freeman-Mills L, Stelloo E, Marchi E, de Bruyn M, Palles C, Nout RA, de Kroon CD, Osse EM, Klenerman P, Creutzberg CL, Tomlinson IP, Smit VT, Nijman HW, Bosse T, Church DN. van Gool IC, et al. Among authors: nijman hw. Clin Cancer Res. 2015 Jul 15;21(14):3347-3355. doi: 10.1158/1078-0432.CCR-15-0057. Epub 2015 Apr 15. Clin Cancer Res. 2015. PMID: 25878334 Free PMC article.
Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
Wouters MC, Komdeur FL, Workel HH, Klip HG, Plat A, Kooi NM, Wisman GB, Mourits MJ, Arts HJ, Oonk MH, Yigit R, de Jong S, Melief CJ, Hollema H, Duiker EW, Daemen T, de Bruyn M, Nijman HW. Wouters MC, et al. Among authors: nijman hw. Clin Cancer Res. 2016 Feb 1;22(3):714-24. doi: 10.1158/1078-0432.CCR-15-1617. Epub 2015 Sep 18. Clin Cancer Res. 2016. PMID: 26384738
207 results